NCT00192374已完成3 期
A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase III, Multicenter Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B,Live, Cold-Adapted (CAIV-T) in Healthy Children
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 1,920
- 试验地点
- 4
- 主要终点
- The primary efficacy endpoint was the first episode in a study child of a culture-confirmed influenza illness, caused by community-acquired subtypes antigenically similar to those contained in the vaccine.
研究概览
简要总结
- Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of(CAIV-T) in Healthy Children.
详细描述
- A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase III, Multicenter Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of Three Dose Levels of a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) in Healthy Children
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 6 Months 至 35 Months（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- ••who are aged at least 6 months and less than 36 months of age at the time of first vaccination
- •who are in good health as determined by medical history, physical examination and clinical judgement
- •whose parent(s)/legal guardian(s) have provided written informed consent after the nature of the study has been explained
- •who, along with their parent(s)/legal guardian(s), will be available for duration of the trial (8 months ±1 month)
- •whose parent(s)/legal guardian(s), can be reached by study staff for the post-vaccination contacts [telephone, clinic or home visit].
排除标准
- •whose parent(s)/legal guardian(s) are perceived to be unavailable or difficult to contact for evaluation or study visits during the study period with any serious chronic disease (e.g., with signs of cardiac or renal failure or severe malnutrition), including progressive neurological disease
- •with Down's syndrome or other known cytogenetic disorders
- •with a known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids (see Section 4.2.1)
- •who received any blood products, including immunoglobulin, in the period from six months prior to vaccination through to the conclusion of the study
- •for whom there is intent to administer any other investigational vaccine or agent from one month prior to enrollment through to the conclusion of the study
- •have an immunosuppressed or an immunocompromised individual living in the same household
- •who, at any time prior to entry into this study, received a dose of any influenza vaccine (commercial or investigational)
- •with a documented history of hypersensitivity to egg or egg protein or any other component of the assigned study vaccine
- •who received aspirin (acetylsalicylic acid) or aspirin-containing products in the two weeks prior to vaccination or for which use is anticipated during the study
- •with any medical conditions that in the opinion of the investigator might interfere with interpretation of the study results. If any of these criteria are met following enrolment, the subject will be excluded from subsequent vaccine dosing.
- •Note: Pregnancy in a household member or any person who has regular contact with the subject is not a contraindication to the enrollment or ongoing participation of the subject in the study.
结局指标
主要结局
The primary efficacy endpoint was the first episode in a study child of a culture-confirmed influenza illness, caused by community-acquired subtypes antigenically similar to those contained in the vaccine.
次要结局
- A secondary efficacy endpoint was the first episode of culture-confirmed influenza illness caused by any community-acquired antigenic subtype.
研究者
研究点 (4)
Loading locations...
相似试验
已完成
3 期
Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult SubjectsInfluenzaNCT00630331Novartis Vaccines11,404
已完成
1 期
Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB5 in Healthy SubjectsHealthyNCT02144714Samsung Bioepis Co., Ltd.189
已完成
1 期
Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB3 in Healthy Male SubjectsHealthyNCT02075073Samsung Bioepis Co., Ltd.109
已完成
1 期
Pharmacokinetic, Safety, Tolerability and Immunogenicity Study of SB2 in Healthy SubjectsHealthyNCT01922336Samsung Bioepis Co., Ltd.159
已完成
3 期
Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm InfantsRespiratory Syncytial Virus InfectionsNCT02325791Regeneron Pharmaceuticals1,177